Unusual Liver Masses? How an Elevated AFP Level Can Signal More Than Just Liver Cancer
"Navigating the complexities of tumor diagnosis when a routine blood test throws you a curveball. Learn how to interpret elevated alpha-fetoprotein levels in the presence of liver masses and the critical steps to take next."
Imagine facing a health scare that begins with vague symptoms like malaise and unexplained weight loss. Routine blood work reveals an elevated alpha-fetoprotein (AFP) level, a marker often associated with liver cancer. Now, picture the added complexity of discovering masses in your liver. The immediate assumption? Hepatocellular carcinoma (HCC), a primary liver cancer. But what if the real culprit is something far less common and initially overlooked?
This is the diagnostic dilemma faced by a 55-year-old man in a recent JAMA Clinical Challenge. His case highlights a crucial lesson for both medical professionals and patients: elevated AFP levels and liver masses don't always equate to HCC. Sometimes, a thorough investigation is needed to uncover the true source of the problem.
In this article, we'll delve into the details of this intriguing case, exploring the diagnostic process, the importance of advanced imaging techniques, and the critical role of biopsy in uncovering the unexpected diagnosis of a pancreatic neuroendocrine tumor (PNET). We'll also discuss how this case underscores the need for vigilance and a broad differential diagnosis when faced with seemingly straightforward medical presentations.
Why AFP Matters
An elevated alpha-fetoprotein (AFP) level can be an important clue when evaluating an unusual liver mass, but it does not identify one diagnosis by itself. AFP results are generally interpreted alongside symptoms, medical history, laboratory findings, and imaging. This broader evaluation helps distinguish possible liver cancer from benign liver conditions and other causes of an abnormal mass.
Screening Requires More Than AFP
AFP testing is used in liver-cancer evaluation, but it has recognized limitations. A study analyzing AFP distributions in more than 4,500 patients with chronic liver disease from Japan and the United Kingdom, along with healthy people without chronic liver disease, defined reference ranges for hepatocellular carcinoma and characterized AFP-negative HCC patients. Because AFP testing alone may miss tumors, complementary imaging such as ultrasound or CT is used, while current screening guidance recommends ultrasound with or without AFP for people at high risk; ultrasound itself may not capture every early lesion.
An Evolving Biomarker
AFP has developed from a standalone laboratory clue into one component of a broader liver-mass evaluation. Its interpretation has increasingly been paired with imaging and clinical assessment rather than treated as definitive on its own. This evolution reflects the recognition that an elevated AFP level can have more than one explanation.
Decoding the Diagnostic Puzzle: When AFP Isn't Just Liver Cancer
Alpha-fetoprotein (AFP) is a protein produced by the liver and yolk sac during fetal development. Its levels typically drop significantly after birth, with only trace amounts detectable in healthy adults. However, elevated AFP levels can be a sign of certain medical conditions, most notably hepatocellular carcinoma (HCC), the most common type of liver cancer. Because of this strong association, doctors often rely on AFP levels as a key diagnostic marker for HCC, especially in patients with chronic liver disease.
- Comprehensive Medical History and Physical Exam: A thorough assessment helps identify potential risk factors for liver disease (alcohol use, hepatitis history) and other relevant medical conditions.
- Advanced Imaging: Techniques like triple-phase CT scans and MRI can provide detailed information about the characteristics of liver masses, helping to distinguish between different types of tumors.
- Biopsy: This is the gold standard for diagnosis. A tissue sample is taken from the liver mass and examined under a microscope to determine the type of cells present and confirm the diagnosis.
Research Beyond a Single Number
Current discussion of AFP increasingly focuses on how the marker should be interpreted in context. Researchers and clinicians are examining reference ranges, imaging combinations, and changes in AFP over time rather than relying only on one threshold. This approach is intended to improve diagnostic accuracy while acknowledging that AFP-negative liver cancers and noncancerous causes of elevation exist.
Where AFP Can Mislead
AFP screening has important failure modes, including false-negative results that may delay liver-cancer diagnosis and treatment. The uncertainty may become more significant as alcohol-associated liver disease and metabolic dysfunction-associated steatotic liver disease become more common, because the test characteristics of AFP in these changing populations remain uncertain. AFP levels may also correlate with tumor burden and aggressiveness in HCC, and post-treatment monitoring may provide information about recurrence, but these prognostic associations do not make AFP diagnostic by itself.
AFP in Context
AFP is most useful when compared with other evidence rather than interpreted in isolation. Imaging can reveal a lesion that AFP does not detect, while clinical history can provide context for an abnormal result. The practical comparison is therefore not AFP versus every other test, but AFP as one part of a combined assessment.
The Takeaway: Think Beyond the Obvious
This case underscores the importance of considering a broad differential diagnosis when evaluating patients with elevated AFP levels and liver masses. While HCC is a common culprit, it's crucial to remember that other conditions can mimic its presentation. Advanced imaging techniques, combined with biopsy, are essential for accurate diagnosis and appropriate treatment. For patients, this means being proactive in discussing all possible diagnoses with your doctor and understanding the rationale behind each diagnostic step. Don't hesitate to ask questions and advocate for thorough investigation, especially when faced with complex medical presentations.
A Clue, Not a Verdict
The central lesson is that an elevated AFP level should prompt careful evaluation, not an automatic cancer diagnosis. Its meaning depends on the patient’s liver condition, imaging findings, and trends over time. A measured interpretation can help clinicians investigate unusual liver masses without overstating what one biomarker can prove.
Trends and Treatment Guidance
The AFP tumor-market report Emerging Trends in the Alpha-fetoprotein (AFP) Tumor Market for Early Cancer Detection valued that market at USD 484 million in 2025 and projected USD 997 million by 2035, although these are market projections rather than clinical outcomes. A July 2025 report described distinct AFP patterns that independently predicted outcomes in unresectable HCC patients treated with lenvatinib, suggesting that AFP trends may eventually help guide therapeutic decisions. Other market analysis covers a 2019-2033 study period, with 2025 as its base and estimated year and 2025-2033 as its forecast period.
Interpretation Across the Care Pathway
AFP interpretation remains controversial because both false-positive and false-negative results can occur, including in people being evaluated for liver transplantation. Elevated AFP is not exclusive to liver cancer and may occur with hepatitis, cirrhosis, liver regeneration, germ cell tumors, and some gastrointestinal cancers. At the same time, early AFP changes have been studied as a possible surrogate for systemic-treatment outcomes in HCC, including treatment with sorafenib and later-line therapies.
Putting Results in Perspective
For patients, an elevated AFP result can be concerning but should be understood as a signal requiring follow-up rather than as a confirmed diagnosis. The next steps generally depend on the complete clinical picture, including imaging and the presence of liver disease or other potential explanations. Clear communication about AFP’s uncertainty can help patients avoid both false reassurance and unnecessary alarm.